PULSE BIOSCIENCES, INC.PLSEEarnings & Financial Report
Colossal Biosciences Inc. is an American biotechnology and genetic engineering company working to de-extinct several extinct animals, including the woolly mammoth, the Tasmanian tiger, the northern white rhinoceros, the dire wolf, the dodo, and the moa. In 2023, it stated that it wants to have woolly mammoth hybrid calves by 2028, and wants to reintroduce them to the Arctic tundra habitat. Likewise, it launched the Tasmanian Thylacine Advisory Committee, a thylacine research project to releas...
PLSE Q3 2025 Key Financial Metrics
Revenue
$86.0K
Gross Profit
$-193.0K
Operating Profit
$-20.4M
Net Profit
$-19.4M
Gross Margin
-224.4%
Operating Margin
-23682.6%
Net Margin
-22540.7%
YoY Growth
N/A
EPS
$-0.29
Financial Flow
PULSE BIOSCIENCES, INC. Q3 2025 Financial Summary
PULSE BIOSCIENCES, INC. reported revenue of $86.0K for Q3 2025, with a net profit of $-19.4M (-22540.7% margin). Cost of goods sold was $279.0K, operating expenses totaled $20.2M.
Key Financial Metrics
| Total Revenue | $86.0K |
|---|---|
| Net Profit | $-19.4M |
| Gross Margin | -224.4% |
| Operating Margin | -23682.6% |
| Report Period | Q3 2025 |
PULSE BIOSCIENCES, INC. Annual Revenue by Year
PULSE BIOSCIENCES, INC. annual revenue history includes year-by-year totals (for example, 2024 revenue was $0).
| Year | Annual Revenue |
|---|---|
| 2024 | $0 |
| 2023 | $0 |
| 2022 | $700.0K |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $86000 |
| YoY Growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $59.2M | $49.2M | $40.4M | $93.0M | $132.5M | $133.4M | $120.3M | $108.8M |
| Liabilities | $14.8M | $12.9M | $13.5M | $13.9M | $17.6M | $14.9M | $15.8M | $16.1M |
| Equity | $44.4M | $36.3M | $27.0M | $79.1M | $114.9M | $118.5M | $104.5M | $92.7M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-6.8M | $-9.8M | $-8.4M | $-9.0M | $-9.1M | $-13.5M | $-12.8M | $-13.0M |
More Companies
ILMN
ILLUMINA, INC.
Revenue
$1.2B
Net Profit
$334.0M
UTHR
UNITED THERAPEUTICS Corp
Revenue
$799.5M
Net Profit
$338.7M
GMAB
GENMAB A/S
Revenue
$925.0M
Net Profit
$336.0M
GH
Guardant Health, Inc.
Revenue
$265.2M
Net Profit
$-92.7M
NBIX
NEUROCRINE BIOSCIENCES INC
Revenue
$805.5M
Net Profit
$153.7M
EXEL
EXELIXIS, INC.
Revenue
$598.7M
Net Profit
$244.5M
MDGL
MADRIGAL PHARMACEUTICALS, INC.
Revenue
$287.3M
Net Profit
$-114.2M
QGEN
QIAGEN N.V.
BMRN
BIOMARIN PHARMACEUTICAL INC
Revenue
$776.1M
Net Profit
$-30.7M
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Revenue
$264.0M
Net Profit
$30.8M